- Home
- PYPD vs INKT Comparison
PYPD vs INKT Comparison
Compare PYPD & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- INKT
- Stock Information
- Founded
- PYPD 2008
- INKT 2017
- Country
- PYPD Israel
- INKT United States
- Employees
- PYPD N/A
- INKT N/A
- Industry
- PYPD Medical/Dental Instruments
- INKT Medicinal Chemicals and Botanical Products
- Sector
- PYPD Health Care
- INKT Health Care
- Exchange
- PYPD Nasdaq
- INKT Nasdaq
- Market Cap
- PYPD 24.2M
- INKT 28.5M
- IPO Year
- PYPD 2020
- INKT 2021
- Fundamental
- Price
- PYPD $3.56
- INKT $0.75
- Analyst Decision
- PYPD Strong Buy
- INKT Strong Buy
- Analyst Count
- PYPD 2
- INKT 2
- Target Price
- PYPD $12.00
- INKT $6.50
- AVG Volume (30 Days)
- PYPD 8.1K
- INKT 32.0K
- Earning Date
- PYPD 11-13-2024
- INKT 11-14-2024
- Dividend Yield
- PYPD N/A
- INKT N/A
- EPS Growth
- PYPD N/A
- INKT N/A
- EPS
- PYPD N/A
- INKT N/A
- Revenue
- PYPD N/A
- INKT N/A
- Revenue This Year
- PYPD N/A
- INKT N/A
- Revenue Next Year
- PYPD N/A
- INKT N/A
- P/E Ratio
- PYPD N/A
- INKT N/A
- Revenue Growth
- PYPD N/A
- INKT N/A
- 52 Week Low
- PYPD $2.95
- INKT $0.57
- 52 Week High
- PYPD $9.20
- INKT $1.90
- Technical
- Relative Strength Index (RSI)
- PYPD 54.93
- INKT 54.46
- Support Level
- PYPD $3.30
- INKT $0.74
- Resistance Level
- PYPD $3.59
- INKT $0.80
- Average True Range (ATR)
- PYPD 0.21
- INKT 0.05
- MACD
- PYPD 0.02
- INKT 0.01
- Stochastic Oscillator
- PYPD 68.27
- INKT 62.60
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.